Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 123353262 | 12335326 | 2 | F | 20160325 | 20160708 | 20160504 | 20160715 | EXP | US-ASTRAZENECA-2016SE46749 | ASTRAZENECA | 28970.00 | DY | F | Y | 0.00000 | 20160716 | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 123353262 | 12335326 | 1 | PS | TAGRISSO | OSIMERTINIB | 1 | Oral | Y | U | 208065 | 80 | MG | TABLET | QD | |||||
| 123353262 | 12335326 | 2 | SS | TAGRISSO | OSIMERTINIB | 1 | Oral | Y | U | 208065 | 80 | MG | TABLET | QD | |||||
| 123353262 | 12335326 | 3 | SS | TAGRISSO | OSIMERTINIB | 1 | Oral | Y | U | 208065 | 40 | MG | TABLET | QD | |||||
| 123353262 | 12335326 | 4 | SS | TAGRISSO | OSIMERTINIB | 1 | Oral | Y | U | 208065 | 40 | MG | TABLET | QD | |||||
| 123353262 | 12335326 | 5 | SS | TAGRISSO | OSIMERTINIB | 1 | Oral | Y | U | 208065 | 40 | MG | TABLET | QD | |||||
| 123353262 | 12335326 | 6 | SS | TAGRISSO | OSIMERTINIB | 1 | Oral | Y | U | 208065 | 40 | MG | TABLET | QD | |||||
| 123353262 | 12335326 | 7 | SS | METOPROLOL TARTRATE. | METOPROLOL TARTRATE | 1 | Oral | 25.0MG UNKNOWN | U | 0 | 25 | MG | |||||||
| 123353262 | 12335326 | 8 | C | VITAMIN D | CHOLECALCIFEROL | 1 | 0 | ||||||||||||
| 123353262 | 12335326 | 9 | C | VITAMIN B12 | CYANOCOBALAMIN | 1 | 0 | ||||||||||||
| 123353262 | 12335326 | 10 | C | XARELTO | RIVAROXABAN | 1 | 0 | ||||||||||||
| 123353262 | 12335326 | 11 | C | BREO ELLIPTA | FLUTICASONE FUROATEVILANTEROL TRIFENATATE | 1 | Respiratory (inhalation) | 0 | |||||||||||
| 123353262 | 12335326 | 12 | C | MAGNESIUM OXIDE. | MAGNESIUM OXIDE | 1 | 0 | ||||||||||||
| 123353262 | 12335326 | 13 | C | POTASSIUM CHLORIDE CRYSTAL ER | 2 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 123353262 | 12335326 | 1 | Non-small cell lung cancer |
| 123353262 | 12335326 | 2 | Lung carcinoma cell type unspecified stage 0 |
| 123353262 | 12335326 | 3 | Non-small cell lung cancer |
| 123353262 | 12335326 | 4 | Lung carcinoma cell type unspecified stage 0 |
| 123353262 | 12335326 | 5 | Non-small cell lung cancer |
| 123353262 | 12335326 | 6 | Lung carcinoma cell type unspecified stage 0 |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 123353262 | 12335326 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 123353262 | 12335326 | Diarrhoea | |
| 123353262 | 12335326 | Electrolyte imbalance | |
| 123353262 | 12335326 | Off label use | |
| 123353262 | 12335326 | Skin exfoliation | |
| 123353262 | 12335326 | Vomiting |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 123353262 | 12335326 | 1 | 20160215 | 20160414 | 0 | |
| 123353262 | 12335326 | 2 | 20160215 | 20160414 | 0 | |
| 123353262 | 12335326 | 3 | 20160415 | 0 | ||
| 123353262 | 12335326 | 4 | 20160415 | 0 | ||
| 123353262 | 12335326 | 5 | 20160512 | 0 | ||
| 123353262 | 12335326 | 6 | 20160512 | 0 |